Skip to main content
Funded Studies

Guus Scheefhals, MSc

CEO at Crossbeta Biosciences and DegenRx

Location: Utrecht Netherlands

Guus Scheefhals, MSc, was appointed Chief Executive Officer of Crossbeta Biosciences in April 2010. Since December 2018, he also has served as CEO of Crossbeta spin-out company DegenRx.

Previously, he worked at Avantium Pharma, beginning in October 2003 as Vice President Business Development Life Sciences. In 2005, he was promoted to Chief Business Officer and member of the Management Team and, in 2009, to Chief Operating Officer.

Prior to his career at Avantium, he gained vast experience in the pharmaceutical industry in several commercial positions. He was Business Development Manager at DSM Biologics from September 1999 to October 2003. Before that, he worked at the Division Pharmaceutical & Industrial R&D of Analytico and the Product Partnering Division of Fresenius. Scheefhals holds a Master's Degree in Pharmacy from the Utrecht University.


Associated Grants

  • Oligomeric Alpha-synuclein-specific Antibody-based Gene Therapy

    2019


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.